Eli Lilly completed a phase 3 trial for its weight loss drug, orforglipron, which showed promising results in evaluating its safety and efficacy for adults with Type 2 diabetes and inadequate glycemic control.
The once-daily oral GLP-1 receptor agonist significantly reduced blood sugar and body weight in adults with Type 2 diabetes and had a safety profile consistent with injectable therapies, according to an April 17 news release from the drugmaker.
In the trial, orforglipron lowered average A1C levels by 1.3% to 1.6% and led to weight loss of up to 16 pounds at the highest dose over 40 weeks. More than 65% of participants reached an A1C level below 6.5%.
Orforglipron is the first small-molecule GLP-1 therapy to successfully complete a phase 3 trial. Eli Lilly plans to submit for regulatory approval for weight management by the end of 2025 and for Type 2 diabetes in 2026.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
